CSPC.Y Aperçu des actions CSPC Pharmaceutical Group Limited, une société holding d'investissement, se consacre à la recherche et au développement, à la fabrication et à la vente de produits pharmaceutiques en République populaire de Chine, dans d'autres régions d'Asie, en Amérique du Nord, en Europe et à l'échelle internationale. Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
CSPC Pharmaceutical Group Limited Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 CSPC Pharmaceutical Group Historique des cours de bourse Prix actuel de l'action HK$2.31 Plus haut sur 52 semaines HK$3.82 Plus bas sur 52 semaines HK$2.25 Bêta 0.65 Variation sur 1 mois -8.21% Variation sur 3 mois -33.91% Variation sur 1 an -34.66% Variation sur 3 ans -51.71% Variation sur 5 ans -50.66% Évolution depuis l'introduction en bourse -22.36%
Nouvelles et mises à jour récentes
CSPC Megalith Biopharmaceutical Co., Ltd. Grants Breakthrough Therapy Designation by the National Medical Products Administration Jan 02
CSPC Pharmaceutical Group Limited's Leuprorelin Extended-Release Injection (SYH9016) Obtains Clinical Trial Approval Dec 30
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval for SYH2062 Injection Dec 26 CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06 Voir plus de mises à jour
CSPC Megalith Biopharmaceutical Co., Ltd. Grants Breakthrough Therapy Designation by the National Medical Products Administration Jan 02
CSPC Pharmaceutical Group Limited's Leuprorelin Extended-Release Injection (SYH9016) Obtains Clinical Trial Approval Dec 30
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval for SYH2062 Injection Dec 26 CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20 CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19
CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024 Aug 21
CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jul 11 CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval
CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 25 CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China May 18
CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024 May 16
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs May 15
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 Apr 28
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S Apr 27
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval Mar 23 CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024 Mar 20
CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration Jan 15
CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA Dec 18
CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets Dec 12
CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China Dec 02
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 29
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 28
CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023 Nov 21
CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China Nov 18
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE Nov 08
CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China Nov 04
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Oct 31
CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors Oct 26
CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA Sep 07
CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval Aug 30
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 25
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023 Aug 24
CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 12
Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161) Jun 30
CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Jun 27 CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301 Jun 09
Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China Jun 07
Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023 Jun 06
CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022 Jun 01
CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023 May 17
CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval Jan 05
Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval Dec 31
CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 30
CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S Dec 23
Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 08
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S Nov 30
CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration Nov 24
CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule Nov 17
CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022 Nov 12
CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director Nov 09
CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002 Oct 28
CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis Sep 10
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on 11 October 2022 Aug 25
CSPC Pharmaceutical Group Limited Announces Completion of Clinical Study of Heterologous Booster Immunization of SARS-CoV-2 mRNA Vaccine Aug 24
Cspc Pharmaceutical Group Limited Announces Selective Ntrk and Ros1 Dual Inhibitor Syhx2009 Obtains Clinical Trial Approval Aug 23
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 20
Cspc Pharmaceutical Group Limited Obtains Duoenda (Mitoxantrone Hydrochloride Liposome Injection) Clinical Trial Approval for the Treatment of Neuromyelitis Optica Spectrum Disorders Aug 19
CSPC Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 24, 2022 Aug 13
CSPC Pharmaceutical Group Announces Resignation of Wu Guizhen as Independent Non-Executive Director Aug 02
CSPC Pharmaceutical Group Limited Announce Biologic License Application for Jmt103 Accepted by the NMPA Jun 23 CSPC Pharmaceutical Group Limited Announces Change of CEO
CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2021 May 27
CSPC Pharmaceutical Group Limited to Report Q1, 2022 Results on May 25, 2022 May 14 CSPC Pharmaceutical Group Limited, Annual General Meeting, May 26, 2022
CSPC Pharmaceutical Group Limited Announces COVID-19 mRNA Vaccine "SYS6006" Obtains Clinical Trial Approval Apr 04
CSPC Pharmaceutical Group Limited (SEHK:1093) acquired 51% stake in Guangzhou Recomgen Biotech Co., Ltd. Feb 09
CSPC Pharmaceutical Group Limited Announces JMT601 (CPO107) Granted Fast Track Designation by U.S. FDA for Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Jan 28
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Announce Approval of IND Application for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer Jan 06
CSPC Pharmaceutical Group Limited Obtains Approval for SYHX2001 Dec 30
CSPC Pharmaceutical Group Limited Announces First Patient Dosed in the Phase 1/2 Clinical Trial of JMT601 in the U.S Dec 15
CSPC Pharmaceutical Group Limited Announces That "Sysa1801" Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 17
CSPC Pharmaceutical Group Limited Obtains Approvals for SYHX1903 May 27
CSPC Pharmaceutical Group Limited announces NBL-015 Obtains Clinical Trial Approval in the U.S May 26
CSPC Pharmaceutical Group Limited Announces Innovative Drug "Syha1811 Tablets" Obtains Clinical Trial Approval in China May 21
CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2020 May 19
CSPC Pharmaceutical Group Limited Announces Dual Inhibitor Jak-Syk "Syhx1901" Obtains Clinical Trial Approval Mar 17 Rendement pour les actionnaires CSPC.Y US Pharmaceuticals US Marché 7D -3.4% -0.6% -0.2% 1Y -34.7% 3.0% 25.8%
Voir le rapport complet des actionnaires
Rendement vs Industrie: CSPC.Y a sous-performé le secteur US Pharmaceuticals qui a rapporté 3 % au cours de l'année écoulée.
Rendement vs marché: CSPC.Y a sous-performé le marché US qui a rapporté 25.8 % au cours de l'année écoulée.
Volatilité des prix Is CSPC.Y's price volatile compared to industry and market? CSPC.Y volatility CSPC.Y Average Weekly Movement 7.1% Pharmaceuticals Industry Average Movement 10.8% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.1%
Cours de l'action stable: CSPC.Y n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CSPC.Y ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise CSPC Pharmaceutical Group Limited, une société holding d'investissement, se consacre à la recherche et au développement, à la fabrication et à la vente de produits pharmaceutiques en République populaire de Chine, dans d'autres régions d'Asie, en Amérique du Nord, en Europe et à l'échelle internationale. L'entreprise exerce ses activités dans les secteurs des médicaments finis, des produits en vrac et des aliments fonctionnels et autres. Elle propose des capsules molles et des injections NBP pour les accidents ischémiques cérébraux aigus ; des capsules et des injections Oulaining pour traiter les troubles légers à modérés de la mémoire et de l'esprit ; Enxi pour traiter la maladie de Parkinson idiopathique de l'adulte ; Duomeisu pour le lymphome, le myélome multiple, les cancers de l'ovaire et du sein et d'autres tumeurs malignes ; Jinyouli pour prévenir la leucopénie et l'infection induite par la chimiothérapie ; et Keaili pour le cancer du sein.
Afficher plus CSPC Pharmaceutical Group Limited Résumé des fondamentaux Comment les bénéfices et les revenus de CSPC Pharmaceutical Group se comparent-ils à sa capitalisation boursière ? CSPC.Y statistiques fondamentales Capitalisation boursière US$6.84b Bénéfices(TTM) US$704.51m Recettes(TTM ) US$4.14b
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) CSPC.Y compte de résultat (TTM ) Recettes CN¥30.27b Coût des recettes CN¥8.90b Marge brute CN¥21.37b Autres dépenses CN¥16.21b Les revenus CN¥5.16b
Derniers bénéfices déclarés
Sep 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) 0.44 Marge brute 70.59% Marge bénéficiaire nette 17.04% Ratio dettes/capitaux propres 1.1%
Quelles ont été les performances à long terme de CSPC.Y?
Voir les performances historiques et les comparaisons Dividendes
6.9% Rendement actuel des dividendes
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2025/01/06 12:29 Cours de l'action en fin de journée 2025/01/03 00:00 Les revenus 2024/09/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes CSPC Pharmaceutical Group Limited est couverte par 49 analystes. 27 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Wai Chak Yuen BOCI Research Ltd. Sharon Shi BOCI Research Ltd. Ethan Cui BofA Global Research
Afficher 46 plus d'analystes 
